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Introduction 
Adalimumab (HUMIRA®) is a TNF-α 
blocking agent approved for several 
autoimmune conditions such as rheumatoid 
arthritis, psoriasis, ankylosing spondylitis, 
and Crohn’s disease. The common side 
effects of adalimumab are headache, rash, 
upper respiratory tract infections, and 
injection site reaction. More cases of 
malignancies, especially lymphoma and 
non-melanoma skin cancer, have been 
observed among patients receiving TNF 
blockers compared to control patients in 
clinical trials.1  The clinical manifestations 
of the side effects of adalimumab, at times,  
can be diagnostic dilemmas. 
 
Case Report 
A 68-year-old man presented to the 
emergency room with a three-month history 
of unintentional weight loss, low-grade 
fevers, night sweats, and lymphadenopathy. 
He also reported generalized abdominal pain 
and anorexia. His past medical history was 
significant for rheumatoid arthritis (RA), 
hypertension, and depression. He had no 
previous surgery. Vital signs on admission 
were stable. The physical examination was 
remarkable for enlarged axillary, cervical, 
and inguinal lymph nodes. Initial laboratory 
tests results revealed pancytopenia and 
slightly elevated creatinine. 
The differential diagnoses at this stage 
included, but was not limited to, malignancy 
(particularly lymphoma), tuberculosis (TB), 
HIV, and thyroid disorders.  The patient also  
 
 
had a history of depression which could 
explain some of his symptoms, such as 
anorexia and weight loss.  
The patient was initially anemic and 
leukopenic. An HIV test was negative. A 
Quantiferon-Gold test for TB was also 
negative.  A CT scan of the abdomen/pelvis 
showed multiple small lymph nodes in the 
aortocaval region. Subsequently, a bone 
marrow aspirate was normocellular. A 
lymph node biopsy did not reveal any 
evidence of lymphoproliferative disorder. 
The patient’s abdominal symptoms 
improved with two days of supportive 
management.  
The patient had been treated with 
adalimumab previously for rheumatoid 
arthritis.  He stopped taking this medication 
five days prior to admission for anticipated 
knee replacement surgery.  After three days 
of hospitalization, anemia and leukopenia 
improved spontaneously and the patient was 
discharged in stable condition. A 
rheumatology consult recommended 
discontinuing adalimumab and initiating 
steroids for rheumatoid arthritis. The 
patient’s lymphadenopathy resolved after 
two weeks. 
 
Discussion 
This case illustrated the potential for 
recognition of serious side effects of 
adalimumab in particular and biologic 
therapies in general.  As reported earlier2, 
the risk of developing lymphoma is 
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increased in several autoimmune diseases. 
However, the French RATIO registry1 
suggested increased incidence of 
lymphomas with the use of anti-TNF 
monoclonal antibody.   
Examining the risk of lymphoma with 
biologic use is complicated by several 
factors. First, although lymphoma is of 
public health importance (it is the fifth most 
common cause of cancer), it is statistically 
rare, affecting about 1 in 5000 people per 
year.3,4 Therefore, very large studies are 
necessary to yield adequate statistical power 
to detect clinically significant lymphoma 
risks of biologics.  
Second, many patients treated with 
biologics have received immuno-
suppressants such as methotrexate (MTX), 
cyclosporine, or azathioprine, either in the 
past, or concurrently with biologics, which 
themselves potentially can increase the risk 
of lymphoma.  Consequently, it is difficult 
to determine which drug, or combination of 
treatments, meaningfully impacts lymphoma 
risk. 
Although the patient described in the 
above case had a negative work-up for 
lymphoma, it was imperative to recognize 
such predictable side effects of adalimumab 
use.  Identifying the side effects of biologic 
therapy is critical to the institution of 
appropriate management of acute illness and 
further follow-up. 
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